Peptide Graded

Mazdutide

Does Mazdutide work?

Yes, in large controlled trials. Trials of 610 and 461 adults, nearly all Chinese.

AStrong human evidenceIn clinical trialsas of 2026-10-27

Mazdutide has completed multiple phase 3 randomized placebo-controlled trials in China: GLORY-1 in 610 adults with overweight or obesity and GLORY-2 in 461 adults with obesity, plus the DREAMS trials in type 2 diabetes, and it won two approvals on that basis. That meets the A definition. The limits are that nearly all trial participants were Chinese, no cardiovascular outcomes trial has reported, and US data are limited to one phase 2 trial of 179 people. 41012

GLORY-1 randomized 610 Chinese adults with overweight or obesity. They got one of two mazdutide doses or placebo for 48 weeks. Weight fell by 12.0 and 14.8 percent at the lower and higher trial doses. On placebo it fell 0.5 percent. Waist size, blood pressure, lipids, uric acid and liver fat also improved. GLORY-2 randomized 461 Chinese adults with obesity (BMI of at least 30). They got a higher trial dose or placebo for 60 weeks. Weight fell 16.65 percent versus 1.50 percent. And 84 percent versus 33 percent lost at least 5 percent. 410

The DREAMS-1 and DREAMS-2 trials were in type 2 diabetes. They compared mazdutide with placebo and with dulaglutide. Mazdutide cut HbA1c and weight more than dulaglutide did. A 2025 systematic review and a 2024 meta-analysis of the randomized trials confirm steady weight and blood sugar effects. A 2026 BMJ network meta-analysis placed mazdutide among the more effective incretin drugs on weight by indirect comparison. But no head-to-head trial against tirzepatide or semaglutide has been published. 35911

Evidence checklist

  • Randomised controlled trial GLORY-1, GLORY-2, DREAMS phase 3 RCTs
  • Human study over 100 people GLORY-1, 610 adults
  • More than one research group Article does not say who ran the trials
  • Clinical outcomes, not surrogate markers Weight and glucose; no outcomes trial yet
  • Human safety data beyond case reports Phase 3 data; US phase 2 only 179 people

Read the full Mazdutide page

More on Mazdutide

Citations

  1. StatPearls: Glucagon-like peptide-1 receptor agonists ncbi.nlm.nih.gov
  2. JAMA 2026: Glucagon receptor agonism in obesity therapeutics doi.org
  3. Drugs 2025: Mazdutide, first approval doi.org
  4. Ji 2025, NEJM: Mazdutide in Chinese adults with overweight or obesity (GLORY-1) doi.org
  5. Diabetes Obes Metab 2025: Systematic review of mazdutide trials doi.org
  6. ClinicalTrials.gov: NCT06124807, US phase 2 trial of mazdutide clinicaltrials.gov
  7. Int J Mol Sci 2022: GLP-1 receptor signaling and insulin secretion doi.org
  8. Diabetes Obes Metab 2024: Glucagon receptor agonism and energy expenditure doi.org
  9. BMJ 2026: Network meta-analysis of incretin-based drugs for weight loss doi.org
  10. JAMA 2026: Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2) pubmed.ncbi.nlm.nih.gov
  11. Front Endocrinol 2024: Meta-analysis of randomized trials of mazdutide doi.org
  12. Hsia 2026, Lancet Diabetes Endocrinol: mazdutide in US adults with obesity or overweight, phase 2 randomized placebo-controlled trial pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Mazdutide article, fact-checked against the cited sources. No dosing anywhere on this site.